Upon further clinicopathologic data analysis, a high expression level of BALR-2 was found to be associated with poor survival and reduced responses to prednisolone used in treatment of B-ALL [166]. The gene discussed is CDK6-AS1; the disease is precursor B-cell acute lymphoblastic leukemia.